In light of the ongoing coronavirus disease (COVID-19) pandemic, PEPperPRINT has rapidly developed and produced a new peptide microarray based on the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral genome. Derived from the virus isolate Wuhan-Hu-1 (GenBank ID: MN908947.3), the new PEPperCHIP® SARS-CoV-2 Proteome Microarray gives researchers access to serologically screen 4,883 individual peptides spanning the entire viral proteome.
*Update 27.03.2020* In collaboration with the Institute of Virology of the Charité, we have screened COVID-19 patient sera in comparison with healthy controls using our PEPperCHIP® SARS-CoV-2 Proteome Microarray. See the first results of the ongoing study here.
Identify, profile, and compare specific IgG, IgA, and IgM antibody responses in patient or animal sera for vaccine development, or screen viral antigens to find and characterize immunodominant epitopes for in-vitro diagnostics research.
Fig.1. Proposed antibody fingerprinting workflow using the PEPperCHIP® SARS-CoV-2 Proteome Microarray. The entire SARS-CoV-2 viral proteome is translated into overlapping peptides and printed onto glass slides. Patient sera is incubated on the chip and antibodies present in the sample bind to epitopes recognized within individual peptides. The resulting response profile may be compared across different samples to monitor B-cell responses over time, or to determine immunodominant epitopes that may be further validated as potential disease-specific biomarkers for IVD development.
The new PEPperCHIP® SARS-CoV-2 Proteome Microarray chip contains a single peptide array and is compatible with a 3/1 well PEPperCHIP® Incubation Tray. Each chip produced comes with HA and polio assay control peptide spots.
Distinct Early IgA Profile May Determine Severity of COVID-19 Symptoms: An Immunological Case Series.
Dahlke, Christine, Jasmin Heidepriem, Robin Kobbe, Rene Santer, Till Koch, Anahita Fathi, My L. Ly, et al. Preprint. Infectious Diseases (except HIV/AIDS), April 17, 2020 [doi.org/10.1101/2020.04.14.20059733]